Today: 28 June 2026
Browse Category

ASX:MSB 3 October 2025 - 6 March 2026

Mesoblast Limited shares rise as Ryoncil launch puts $120 million sales target in play

Mesoblast Limited shares rise as Ryoncil launch puts $120 million sales target in play

Mesoblast shares rose 3% in early U.S. trading Friday after the company reported first-half revenue of $51.3 million, up from $3.2 million a year earlier, driven by Ryoncil sales. The company set a fiscal 2026 net revenue target of $110–$120 million for Ryoncil and said 49 transplant centers have been onboarded. Cash stood at $130 million as of Dec. 31. An adult trial for Ryoncil is expected to begin after ethics approval in March.
6 March 2026
·
Australia stock market today: ASX 200 closes higher as tech rebounds; BlueScope pushes back on $13.2b bid

Australia stock market today: ASX 200 closes higher as tech rebounds; BlueScope pushes back on $13.2b bid

The S&P/ASX 200 closed up 0.29% at 8,720.8, led by gains in tech and healthcare, while miners fell. BlueScope rejected a A$13.2 billion takeover bid from SGH and Steel Dynamics. Ansell shares dropped 6.2% as CEO Neil Salmon announced his retirement, with Nathalie Ahlström set to take over in February. The Australian dollar slipped to about 67 U.S. cents.
8 January 2026
·········
Australian Stock Market Today: ASX 200 Climbs 0.8% as Takeover Deals, CPI Shock and Retail Rout Shape 26 November 2025

Australian Stock Market Today: ASX 200 Climbs 0.8% as Takeover Deals, CPI Shock and Retail Rout Shape 26 November 2025

The S&P/ASX 200 rose 0.81% to 8,606.5 Wednesday, shrugging off a jump in annual inflation to 3.8%. Temple & Webster plunged 32% after weak revenue growth, while National Storage REIT surged nearly 20% on a $4 billion takeover bid. The Australian dollar climbed to US$0.6505. Miners and healthcare stocks led gains.
26 November 2025
·········
Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast Stock Jumps on Ryoncil Milestone – Analysts See 40% Upside

Mesoblast shares closed at $17.02 on Oct. 2, up 4.6% after the FDA-approved Ryoncil won permanent CMS reimbursement via a new J-code. The company confirmed its cell therapies are made from U.S. donors and not subject to tariffs. Wall Street consensus is “Buy” with a $24 average price target. Hedge funds have increased stakes, but overall institutional ownership remains low.
3 October 2025
··

Stock Market Today

  • Baidu Stock Valuation After Volatile Year: Is Current Price Attractive?
    June 28, 2026, 5:58 AM EDT. Baidu (NasdaqGS:BIDU) has returned 21% over the past year despite a 30.7% decline year-to-date amid shifting investor sentiment on Chinese tech and regulatory risks. The stock trades close to its intrinsic value at $102.81 based on a Discounted Cash Flow (DCF) analysis, just 1.4% above the current price, suggesting fair valuation. Baidu scores 2/6 on valuation checks, indicating mixed signals on undervaluation. Free cash flow estimates point to improvement by 2029, though recent figures showed losses. Price-to-sales ratio analysis also factors into assessing investor pricing against revenue. Overall, Baidu's stock price reflects the balance between growth prospects and regulatory concerns, warranting close monitoring for investors seeking opportunities in volatile Chinese tech stocks.

Latest articles

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 28.06.2026

28 June 2026
LIVEMarkets rolling coverageStarted: June 28, 2026, 4:00 AM EDTUpdated: June 28, 2026, 5:58 AM EDT Baidu Stock Valuation After Volatile Year: Is Current Price Attractive? June 28, 2026, 5:58 AM EDT. Baidu (NasdaqGS:BIDU) has returned 21% over the past year despite a 30.7% decline year-to-date amid shifting investor sentiment on Chinese tech and regulatory risks. The stock trades close to its intrinsic value at $102.81 based on a Discounted Cash Flow (DCF) analysis, just 1.4% above the current price, suggesting fair valuation. Baidu scores 2/6 on valuation checks, indicating mixed signals on undervaluation. Free cash flow estimates point to improvement
Go toTop